Product information and disease descriptionPlace of product in therapyApproaches to treatment
Expected outcomes of therapy
14 evidence topics · 16 sources
Summary: expected outcomes
AMPLITUDE is designed to assess the effect of inaxaplin on kidney function and proteinuria. In the phase 2a study, proteinuria decreased by day 15 and continued to decrease through week 13. The phase 2a study reported a mean UPCR change of -47.6% (95% CI -60.0 to -31.3) at week 13; its authors cite data from nearly 30,000 participants in which a 30% albuminuria reduction corresponded to a 27% lower risk of a composite kidney endpoint, and state as a hypothesis to be tested that a longer treatment period may prevent or slow progression to end-stage kidney disease. The AMPLITUDE final analysis uses eGFR slope after two years as the primary efficacy endpoint and time to a composite of a sustained eGFR decline of 30% or more, end-stage kidney disease, or death as the secondary endpoint, assessed when approximately 187 composite outcomes have occurred. Across CKD trials, each 30% reduction in albuminuria was associated with a 27% lower hazard of the clinical endpoint (41 treatment comparisons, 29,979 participants) or a 19% lower hazard (48 trials, 85,681 participants), and a 0.75 mL/min/1.73 m2 per year greater treatment effect on total GFR slope with a 23.3% lower hazard. In FSGS, a partial remission defined as a 40% proteinuria reduction with proteinuria below 1.5 g/g was associated with less progression (hazard ratio 0.30 at month 8), and a 2025 review found that further work is needed to define a treatment effect short of complete remission as an endpoint. The only AMKD-specific analysis found, a preprint of 128 participants, estimated that a 50% reduction in UACR at 12 months was associated with a 28% lower risk of a kidney composite endpoint. The sources reviewed give no estimate of the delay in kidney failure expected with inaxaplin; Vertex states that people with AMKD reach kidney failure at a median age of 45 years.
Inaxaplin: proteinuria reduction and the hypothesized effect on progression
AMPLITUDE: endpoints that will measure clinical outcomes
Albuminuria change as a surrogate endpoint: meta-analysis of 41 treatment comparisons
“We identified 41 eligible treatment comparisons from randomised trials (referred to as studies) that provided sufficient patient-level data on 29 979 participants (21 206 [71%] with diabetes).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across all studies, with a meta-regression slope of 0·89 (95% Bayesian credible interval [BCI] 0·13-1·70), each 30% decrease in geometric mean albuminuria by the treatment relative to the control was associated with an average 27% lower hazard for the clinical endpoint (95% BCI 5-45%; median R2 0·47, 95% BCI 0·02-0·96).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria change as a surrogate endpoint: meta-analysis of 48 trials
“Here, in an individual participant data analysis of 48 randomized controlled trials (studies) involving 85,681 participants, we assessed the association between treatment effects on 6-month urinary albumin:creatinine ratio (UACR) change and the established clinical endpoint of kidney failure or doubling of serum creatinine concentrations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across all trials, each 30% reduction in the geometric mean of the UACR in the treatment group relative to the control group was associated with an average of 19% lower hazard for the clinical endpoint (95% Bayesian credible interval (BCI): 5-30%); median coefficient of determination (R2) = 0.66 (95% BCI: 0.06-0.98). There was no clear evidence that this association varied by CKD etiology.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
GFR slope as a surrogate endpoint: meta-analysis of 66 studies
“Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median R2=0.97 [95% Bayesian credible interval [BCI] 0.82 to 1.00]), and moderately associated with those on chronic slope (R2=0.55 [95% BCI 0.25 to 0.77]). There was no evidence of heterogeneity across disease. Our results support use of total slope as a primary endpoint for clinical trials of CKD progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“indicating that a 0.75 ml/min per 1.73 m2/year greater beneficial effect of the treatment on the total GFR slope is associated with an average 23.3% lower hazard ratio for the clinical end point (95% BCI 19.3% to 27.2%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria and GFR slope as joint surrogate endpoints
“The predicted probability of clinical benefit when considering both surrogates was determined primarily by estimated treatment effects on UACR when sample size was small (approximately 60 patients per treatment arm) and follow-up brief (approximately 1 year), with the importance of GFR slope increasing for larger sample sizes and longer follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
National Kidney Foundation, FDA, and EMA scientific workshop on surrogate endpoints
“In March 2018, the National Kidney Foundation sponsored a scientific workshop in collaboration with the FDA and EMA to evaluate changes in albuminuria or GFR as candidate surrogate end points.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that both early change in albuminuria and GFR slope fulfill criteria for surrogacy for use as end points in clinical trials for chronic kidney disease progression under certain conditions, with stronger support for change in GFR than albuminuria.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Proteinuria remission and kidney survival in FSGS
“A novel definition of partial remission (40% proteinuria reduction and proteinuria<1.5 g/g) on the basis of receiver operating curve analyses of 89 patients was identified (Sensitivity=0.70; Specificity=0.77).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Propensity score–adjusted analyses showed the novel partial remission was associated with less progression at months 4 and 8 (month 4: hazard ratio, 0.50; P=0.01; month 8: hazard ratio, 0.30; P=0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 1 unit reduction in log-transformed urinary protein:creatinine ratio was associated with a 3.90 ml/year rise in eGFR (95% CI=2.01 to 5.79).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was an analogous relationship between time-varying proteinuria and time to end-stage kidney disease: the HR for ESKD or death per 1 unit reduction in log-transformed urinary protein-creatinine ratio was 0.23 (95% CI=0.12 to 0.44).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proteinuria endpoints in FSGS trials: Kidney Health Initiative review
“Available data support the use of complete remission of proteinuria in patients with heavy proteinuria as a surrogate endpoint for progression to kidney failure. While substantial treatment effects on proteinuria that are short of a complete remission may also predict the effect of a treatment on progression to kidney failure, further work is needed to determine how such an endpoint should be defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Reasonably likely surrogate endpoints and accelerated approval
“We conclude that data support the use of proteinuria reduction as a reasonably likely surrogate end point for a treatment’s effect on progression to ESKD in IgAN. In the United States, reasonably likely surrogate end points can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN. The clinical benefit of products approved under this program would need to be verified in a postmarketing confirmatory trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Albuminuria change as a surrogate endpoint in AMKD: real-world analysis (preprint)
“Recently, proteinuria has been accepted as a surrogate end point for clinical trials in focal segmental glomerulosclerosis (FSGS) ang IgA nephropathy. However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Real world data (RWD) analysis of 128 patients of African ancestry with APOL1 high risk genotypes, without diabetes, enrolled in the Million Veteran Program (MVP; n=109) or the biorepository at Vanderbilt University (BioVU; n=19), who had urine albumin-creatinine ratio (UACR) >= 420 mg/g (PCR~0.9 g/g) with a concurrent GFR value.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expected benefits of an APOL1-targeted treatment: expert consensus
“Important potential benefits of a treatment for APOL1-associated nephropathy becoming available include:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Slowing kidney disease progression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Extending life expectancy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reducing the incidence of ESKD in the Black population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reducing the number of people requiring a kidney transplant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote